Phase II Study of ASP3550 [degarelix] - A Maintenance-dose Finding Study in Patients With Prostate Cancer.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 19 Feb 2011 Results presented at the 2011 Genitourinary Cancers Symposium.
- 18 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Oct 2008 Actual patient number (273) added as reported by ClinicalTrials.gov.